Dudediligence.

Neurocrine Biosciences, Inc

NBIXNASDAQ · Biological Products, (No Diagnostic Substances)
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$622.1MSep ’24$627.7MDec ’24$572.6MMar ’25$687.5MJun ’25$794.9MSep ’25$805.5MDec ’25$814.5MMar ’26$959.0MJun ’26
Net income, by quarter
$129.8MSep ’24$103.1MDec ’24$7.9MMar ’25$107.5MJun ’25$209.5MSep ’25$153.7MDec ’25$197.9MMar ’26$144.4MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue$1.13B$1.49B$1.89B$2.36B$2.86B
Gross profit$1.12B$1.47B$1.85B$2.32B$2.81B
Operating income$102.5M$249.0M$250.9M$570.5M$619.1M
Net income$89.6M$154.5M$249.7M$341.3M$478.6M
Operating cash flow$256.5M$339.4M$389.9M$595.4M$782.7M
Free cash flow$233.1M$322.9M$361.6M$557.2M$748.7M
Cash$340.8M$262.9M$251.1M$233.0M$713.0M
Shares outstanding94.9M96.5M98.7M99.4M100.1M